Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Emily Lichtenstein"'
2
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Autor: Codruta Chiuzan, Ahmed Sawas, Hye A. Kim, Aishling M. Rada, Mark A. Francescone, Jennifer E Amengual, Laine Atkins, Renee Lichtenstein, Lorenzo Falchi, Lawrence B. Schwartz, Emily Lichtenstein, Changchun Deng, Serge Cremers, Enrica Marchi, Jennifer K. Lue, Matko Kalac, Owen A. O'Connor, Karen Khan
Publikováno v: Blood. 131:397-407
Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractory PT
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0df60efecae1bb65e5bde675ddf46e
https://doi.org/10.1182/blood-2017-09-806737
Zobrazit plný text záznamu
4
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
Autor: Jennifer E Amengual, Owen A. O'Connor, Donald Steven Colbourn, Changchun Deng, Lawrence H. Schwartz, Ahmed Sawas, Lorenzo Falchi, Karen Khan, Emily Lichtenstein
Publikováno v: Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-4 (2016)
Journal of Hematology & Oncology
Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this population but r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7e39637b15f0ab2b28502cf277c0287
http://link.springer.com/article/10.1186/s13045-016-0363-1
Zobrazit plný text záznamu
8
PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses
Autor: Jennifer E Amengual, Ahmed Sawas, Changchun Deng, Lawrence H. Schwartz, Emily Lichtenstein, Lorenzo Falchi, Owen A. O'Connor, Karen Khan
Publikováno v: Blood. 128:2999-2999
Background: Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) represent an unmet medical need. Allogeneic SCT can be curative, but is burdened with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66d2a27ab931ed11345ca8dfd3f3e799
https://doi.org/10.1182/blood.v128.22.2999.2999
Zobrazit plný text záznamu
9
Development of novel backbones for the treatment of peripheral T-cell lymphoma (PTCL): The pralatrexate/romidepsin doublet
Autor: Ahmed Sawas, Donald Steven Colbourn, Michael J. Smith, Changchun Deng, Renee Lichtenstein, Emily Lichtenstein, Karen Khan, Owen A. O'Connor, Jennifer E Amengual, Celeste Rojas, Heather Dials
Publikováno v: Journal of Clinical Oncology. 34:2552-2552
2552Background: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas in which only 20-25% of patients experience long-term survival with CHOP chemotherapy. Recently several drugs...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d57405397e37305304bf9e8d24a75e4d
https://doi.org/10.1200/jco.2016.34.15_suppl.2552
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje